Search

Displaying results 3491 - 3500 of 7897 in total
  1. Drug

    Hu-PHEC Liver

    go.drugbank.com/drugs/DB18347
    Experimental

    Hu-PHEC Liver is an adult hemogenic endothelial cells.

  2. Drug

    NN-8828

    go.drugbank.com/drugs/DB18361
    Investigational

    NN-8828 is an anti-interleukin 21 monoclonal antibody.

  3. Drug

    AVE9633

    go.drugbank.com/drugs/DB06318
    Investigational

    AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.

  4. Drug

    TG100-115

    go.drugbank.com/drugs/DB05552
    Investigational

    An NSAID that inhibits PI-3K gamma and delta.

  5. Drug

    Phentolamine

    go.drugbank.com/drugs/DB00692
    ApprovedInvestigational

    Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation.

  6. Drug

    Tridolgosir

    go.drugbank.com/drugs/DB02034
    Experimental

    An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.

  7. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    [A188580,T756] A similar drug used in the treatment of other types of DMD is [eteplirsen], which targets a different genetic mutation. … Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD).

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801.

  9. Drug

    Iproclozide

    go.drugbank.com/drugs/DB09247
    ApprovedWithdrawn

    Although it was employed as an antidepressant for a time, the fact that the agent is capable of causing fulminant hepatitis and that its use has been documented as the cause for at least three reported … Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI).

  10. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend ledipasvir as a first line